Zhao Shuangtao, Fang Shuangsang, Liu Yanhua, Li Xixi, Liao Shengyou, Chen Jinwen, Liu Jingjia, Zhao Lianhe, Li Hui, Zhou Wei, Shen Wenzhi, Dong Xiaoli, Xiang Rong, Wang Luhua, Zhao Yi
Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
The Key Laboratory of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China.
Oncotarget. 2017 May 23;8(21):34374-34386. doi: 10.18632/oncotarget.16163.
Long non-coding RNAs are known to be involved in cancer progression, but their biological functions and prognostic values are still largely unexplored in diffuse large B-cell lymphoma. In this study, long non-coding RNAs expression was characterized in 1,403 samples including normal and diffuse large B-cell lymphoma by repurposing 7 microarray datasets. Compared with any stage of normal B cells, NONHSAG026900 expression was significantly decreased in tumor samples. And in germinal center B-cell subtype, the significantly higher expression of NONHSAG026900 indicated it was a favorable prognosis biomarker. Then the prognostic power of NONHSAG026900 was validated with another independent dataset and NONHSAG026900 improved the predictive power of International Prognostic Index as an independent factor. Moreover, functional prediction and validation demonstrated that NONHSAG026900 could inhibit cell cycle activity to restrain tumor proliferation. These findings identified NONHSAG026900 as a novel prognostic biomarker and offered a new therapeutic target for diffuse large B-cell lymphoma patients.
已知长链非编码RNA参与癌症进展，但其生物学功能和预后价值在弥漫性大B细胞淋巴瘤中仍大多未被探索。在本研究中，通过重新利用7个微阵列数据集，对包括正常和弥漫性大B细胞淋巴瘤在内的1403个样本中的长链非编码RNA表达进行了表征。与正常B细胞的任何阶段相比，肿瘤样本中NONHSAG026900的表达显著降低。在生发中心B细胞亚型中，NONHSAG026900的显著高表达表明它是一个预后良好的生物标志物。然后，用另一个独立数据集验证了NONHSAG026900的预后能力，并且NONHSAG026900作为一个独立因素提高了国际预后指数的预测能力。此外，功能预测和验证表明，NONHSAG026900可以抑制细胞周期活性以抑制肿瘤增殖。这些发现确定NONHSAG026900为一种新的预后生物标志物，并为弥漫性大B细胞淋巴瘤患者提供了一个新的治疗靶点。
